BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 25099366)

  • 1. Achievements and challenges of adoptive T cell therapy with tumor-infiltrating or blood-derived lymphocytes for metastatic melanoma: what is needed to achieve standard of care?
    Svane IM; Verdegaal EM
    Cancer Immunol Immunother; 2014 Oct; 63(10):1081-91. PubMed ID: 25099366
    [TBL] [Abstract][Full Text] [Related]  

  • 2. White paper on adoptive cell therapy for cancer with tumor-infiltrating lymphocytes: a report of the CTEP subcommittee on adoptive cell therapy.
    Weber J; Atkins M; Hwu P; Radvanyi L; Sznol M; Yee C;
    Clin Cancer Res; 2011 Apr; 17(7):1664-73. PubMed ID: 21325070
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adoptive cell transfer using autologous tumor infiltrating lymphocytes in gynecologic malignancies.
    Mayor P; Starbuck K; Zsiros E
    Gynecol Oncol; 2018 Aug; 150(2):361-369. PubMed ID: 29803316
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical responses in a phase II study using adoptive transfer of short-term cultured tumor infiltration lymphocytes in metastatic melanoma patients.
    Besser MJ; Shapira-Frommer R; Treves AJ; Zippel D; Itzhaki O; Hershkovitz L; Levy D; Kubi A; Hovav E; Chermoshniuk N; Shalmon B; Hardan I; Catane R; Markel G; Apter S; Ben-Nun A; Kuchuk I; Shimoni A; Nagler A; Schachter J
    Clin Cancer Res; 2010 May; 16(9):2646-55. PubMed ID: 20406835
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II clinical trial of adoptive cell therapy for patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and low-dose interleukin-2.
    Nguyen LT; Saibil SD; Sotov V; Le MX; Khoja L; Ghazarian D; Bonilla L; Majeed H; Hogg D; Joshua AM; Crump M; Franke N; Spreafico A; Hansen A; Al-Habeeb A; Leong W; Easson A; Reedijk M; Goldstein DP; McCready D; Yasufuku K; Waddell T; Cypel M; Pierre A; Zhang B; Boross-Harmer S; Cipollone J; Nelles M; Scheid E; Fyrsta M; Lo CS; Nie J; Yam JY; Yen PH; Gray D; Motta V; Elford AR; DeLuca S; Wang L; Effendi S; Ellenchery R; Hirano N; Ohashi PS; Butler MO
    Cancer Immunol Immunother; 2019 May; 68(5):773-785. PubMed ID: 30747243
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adoptive T-cell therapy using autologous tumor-infiltrating lymphocytes for metastatic melanoma: current status and future outlook.
    Wu R; Forget MA; Chacon J; Bernatchez C; Haymaker C; Chen JQ; Hwu P; Radvanyi LG
    Cancer J; 2012; 18(2):160-75. PubMed ID: 22453018
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-Lasting Complete Responses in Patients with Metastatic Melanoma after Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes and an Attenuated IL2 Regimen.
    Andersen R; Donia M; Ellebaek E; Borch TH; Kongsted P; Iversen TZ; Hölmich LR; Hendel HW; Met Ö; Andersen MH; Thor Straten P; Svane IM
    Clin Cancer Res; 2016 Aug; 22(15):3734-45. PubMed ID: 27006492
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic efficacy of melanoma-reactive TIL injected in stage III melanoma patients.
    Labarrière N; Pandolfino MC; Gervois N; Khammari A; Tessier MH; Dréno B; Jotereau F
    Cancer Immunol Immunother; 2002 Nov; 51(10):532-8. PubMed ID: 12384804
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Minimally cultured or selected autologous tumor-infiltrating lymphocytes after a lympho-depleting chemotherapy regimen in metastatic melanoma patients.
    Besser MJ; Shapira-Frommer R; Treves AJ; Zippel D; Itzhaki O; Schallmach E; Kubi A; Shalmon B; Hardan I; Catane R; Segal E; Markel G; Apter S; Nun AB; Kuchuk I; Shimoni A; Nagler A; Schachter J
    J Immunother; 2009 May; 32(4):415-23. PubMed ID: 19342963
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TGF-beta1 induces preferential rapid expansion and persistence of tumor antigen-specific CD8+ T cells for adoptive immunotherapy.
    Liu S; Etto T; Rodríguez-Cruz T; Li Y; Wu C; Fulbright OJ; Hwu P; Radvanyi L; Lizée G
    J Immunother; 2010 May; 33(4):371-81. PubMed ID: 20386469
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization and comparison of 'standard' and 'young' tumour-infiltrating lymphocytes for adoptive cell therapy at a Danish translational research institution.
    Donia M; Junker N; Ellebaek E; Andersen MH; Straten PT; Svane IM
    Scand J Immunol; 2012 Feb; 75(2):157-67. PubMed ID: 21955245
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Infusion of Melan-A/Mart-1 specific tumor-infiltrating lymphocytes enhanced relapse-free survival of melanoma patients.
    Benlalam H; Vignard V; Khammari A; Bonnin A; Godet Y; Pandolfino MC; Jotereau F; Dreno B; Labarrière N
    Cancer Immunol Immunother; 2007 Apr; 56(4):515-26. PubMed ID: 16874485
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized selection design trial evaluating CD8+-enriched versus unselected tumor-infiltrating lymphocytes for adoptive cell therapy for patients with melanoma.
    Dudley ME; Gross CA; Somerville RP; Hong Y; Schaub NP; Rosati SF; White DE; Nathan D; Restifo NP; Steinberg SM; Wunderlich JR; Kammula US; Sherry RM; Yang JC; Phan GQ; Hughes MS; Laurencot CM; Rosenberg SA
    J Clin Oncol; 2013 Jun; 31(17):2152-9. PubMed ID: 23650429
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Key Factors in Clinical Protocols for Adoptive Cell Therapy in Melanoma.
    Considine B; Hurwitz ME
    Methods Mol Biol; 2020; 2097():309-327. PubMed ID: 31776935
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is antigen specificity the key to efficient adoptive T-cell therapy?
    Labarriere N; Khammari A; Lang F; Dreno B
    Immunotherapy; 2011 Apr; 3(4):495-505. PubMed ID: 21463191
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Flow cytometry assessment of residual melanoma cells in tumor-infiltrating lymphocyte cultures.
    Richards JO; Treisman J; Garlie N; Hanson JP; Oaks MK
    Cytometry A; 2012 May; 81(5):374-81. PubMed ID: 22467596
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MART-1-specific melanoma tumor-infiltrating lymphocytes maintaining CD28 expression have improved survival and expansion capability following antigenic restimulation in vitro.
    Li Y; Liu S; Hernandez J; Vence L; Hwu P; Radvanyi L
    J Immunol; 2010 Jan; 184(1):452-65. PubMed ID: 19949105
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Focus on adoptive T cell transfer trials in melanoma.
    Hershkovitz L; Schachter J; Treves AJ; Besser MJ
    Clin Dev Immunol; 2010; 2010():260267. PubMed ID: 21234353
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cell therapy: achievements and perspectives.
    Bordignon C; Carlo-Stella C; Colombo MP; De Vincentiis A; Lanata L; Lemoli RM; Locatelli F; Olivieri A; Rondelli D; Zanon P; Tura S
    Haematologica; 1999 Dec; 84(12):1110-49. PubMed ID: 10586214
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cancer regression in patients with metastatic melanoma after the transfer of autologous antitumor lymphocytes.
    Rosenberg SA; Dudley ME
    Proc Natl Acad Sci U S A; 2004 Oct; 101 Suppl 2(Suppl 2):14639-45. PubMed ID: 15381769
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.